Aktienanalyse zu AN2 Therapeutics Inc (ANTX)ANTXAN2 Therapeutics Inc

AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ANTX is a good buy right now due to its recent FDA clearance for the epetraborole drug, which is expected to drive future growth. The current price is $4.35, significantly below the analyst target of $9, suggesting a potential upside of over 100%. Additionally, the stock has shown a strong year-to-date change of +291.89%, indicating robust momentum. However, a risk to consider is the company's ongoing net losses, which reached $10.03 million in Q1 2026, reflecting the need for continued investment in R&D.